- Home
- IGMS vs GLRE Comparison
IGMS vs GLRE Comparison
Compare IGMS & GLRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- GLRE
- Stock Information
- Founded
- IGMS 1993
- GLRE 2004
- Country
- IGMS United States
- GLRE Cayman Islands
- Employees
- IGMS N/A
- GLRE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- GLRE Property-Casualty Insurers
- Sector
- IGMS Health Care
- GLRE Finance
- Exchange
- IGMS Nasdaq
- GLRE Nasdaq
- Market Cap
- IGMS 528.6M
- GLRE 471.2M
- IPO Year
- IGMS 2019
- GLRE 2007
- Fundamental
- Price
- IGMS $7.48
- GLRE $14.44
- Analyst Decision
- IGMS Buy
- GLRE
- Analyst Count
- IGMS 8
- GLRE 0
- Target Price
- IGMS $16.25
- GLRE N/A
- AVG Volume (30 Days)
- IGMS 213.0K
- GLRE 83.1K
- Earning Date
- IGMS 11-08-2024
- GLRE 11-04-2024
- Dividend Yield
- IGMS N/A
- GLRE N/A
- EPS Growth
- IGMS N/A
- GLRE N/A
- EPS
- IGMS N/A
- GLRE 2.53
- Revenue
- IGMS $2,918,000.00
- GLRE $702,254,000.00
- Revenue This Year
- IGMS $386.95
- GLRE N/A
- Revenue Next Year
- IGMS N/A
- GLRE N/A
- P/E Ratio
- IGMS N/A
- GLRE $5.76
- Revenue Growth
- IGMS 57.64
- GLRE 8.96
- 52 Week Low
- IGMS $6.17
- GLRE $10.95
- 52 Week High
- IGMS $22.50
- GLRE $15.82
- Technical
- Relative Strength Index (RSI)
- IGMS 31.94
- GLRE 41.91
- Support Level
- IGMS $7.00
- GLRE $14.72
- Resistance Level
- IGMS $10.80
- GLRE $15.02
- Average True Range (ATR)
- IGMS 1.02
- GLRE 0.29
- MACD
- IGMS -0.10
- GLRE -0.09
- Stochastic Oscillator
- IGMS 10.39
- GLRE 10.48
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.